Landos Biopharma, Inc.

NasdaqCM:LABP Stock Report

Market Cap: US$71.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Landos Biopharma Past Earnings Performance

Past criteria checks 0/6

Landos Biopharma's earnings have been declining at an average annual rate of -8.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 100% per year.

Key information

-8.5%

Earnings growth rate

25.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-100.0%
Return on equity-107.1%
Net Marginn/a
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Mar 22
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer

Sep 06

Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Aug 19
Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

May 05
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Nov 17
Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Jun 14

Landos Biopharma (LABP) Investor Presentation - Slideshow

Jun 08

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

May 04
We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

Revenue & Expenses Breakdown

How Landos Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:LABP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 240-251412
31 Dec 230-221112
30 Sep 230-211113
30 Jun 230-231114
31 Mar 230-301418
31 Dec 220-391526
30 Sep 220-541836
30 Jun 220-591940
31 Mar 2218-431645
31 Dec 2118-381542
30 Sep 2118-301038
30 Jun 2118-25836
31 Mar 210-34728
31 Dec 200-30525
30 Sep 200-22419
30 Jun 200-17314
31 Mar 200-16214
31 Dec 190-13112

Quality Earnings: LABP is currently unprofitable.

Growing Profit Margin: LABP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LABP is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare LABP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LABP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).


Return on Equity

High ROE: LABP has a negative Return on Equity (-107.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/26 01:42
End of Day Share Price 2024/05/24 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Landos Biopharma, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robin Garner KalleyCraig-Hallum Capital Group LLC
Raghuram SelvarajuH.C. Wainwright & Co.
Christopher HowertonJefferies LLC